The Claim

Removed black-box warnings on menopause hormone therapies to empower access to women’s health.

The Claim, Unpacked

What is literally being asserted?

The administration removed black-box warnings — the FDA’s most serious regulatory warning short of pulling a drug from the market — from hormone replacement therapy (HRT) products used to treat menopausal symptoms. The stated purpose was to expand women’s access to these treatments.

What is being implied but not asserted?

The claim implies that the black-box warnings were unjustified impediments to women’s health — that they were wrong from the start and that the administration corrected a scientific mistake. The framing suggests this was straightforwardly pro-women and uncontroversial. The phrase “empower access” implies that women were being denied beneficial treatment due to excessive regulation.

What is conspicuously absent?

The claim omits several significant elements: that the underlying evidence genuinely does support reconsidering the warnings, but the process by which the administration acted was criticized by the very medical organizations that supported the policy change; that the warnings were not entirely unfounded — combination HRT (estrogen plus progestogen) does carry a real, if modest, increased breast cancer risk that persists with duration of use; that the FDA bypassed its standard advisory committee process in favor of a hand-picked expert panel that critics described as one-sided; and that the endometrial cancer warning on estrogen-alone products was retained, meaning not all black-box warnings were removed. Perhaps most importantly, it omits the distinction between the underlying scientific question (where the evidence genuinely has evolved) and the regulatory process question (where the administration’s approach drew substantial criticism).

Evidence Assessment

Established Facts

The FDA added black-box warnings to all estrogen-containing menopausal HRT products in 2003, following the 2002 Women’s Health Initiative trial results. ¹ The WHI enrolled 16,608 postmenopausal women in a randomized controlled trial of conjugated equine estrogens plus medroxyprogesterone acetate. The trial was stopped early in July 2002 after a mean 5.2 years of follow-up when researchers found a hazard ratio of 1.26 (95% CI 1.00-1.59) for breast cancer with 290 cases, along with increased risks of stroke, coronary heart disease, and venous thromboembolism. The FDA subsequently placed its most prominent safety warning on all estrogen-containing products, including low-dose vaginal formulations, without differentiation by dose, formulation, or route of administration.

The WHI study had significant methodological limitations that subsequent analyses have clarified. ² Sixty-eight percent of WHI participants were 60 years or older at enrollment, with a mean age of 63 — over a decade past typical menopause onset. The study used specific formulations (oral conjugated equine estrogens and medroxyprogesterone acetate) that differ from modern HRT regimens. Follow-up reanalyses, including the WHI’s own subgroup analyses, revealed that outcomes varied substantially by age at initiation. Women aged 50-59 who received estrogen alone showed a relative risk of 0.56 for coronary heart disease, compared to 1.04 for women aged 70-79. With over 20 years of follow-up, estrogen-alone HRT was found to reduce breast cancer risk by approximately 22% in women with prior hysterectomy.

HRT use among postmenopausal women declined dramatically after the WHI publication, from approximately 27% in 1999 to roughly 5% by 2020. ³ This decline affected women across all age groups, including younger menopausal women in their 50s who, subsequent evidence suggests, stood to benefit most. In 2020, only about 2 million women aged 46-65 received an HRT prescription, despite approximately 41 million U.S. women being in the 45-64 age range.

On November 10, 2025, HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary announced the initiation of black-box warning removal from HRT products. ⁴ The FDA stated it would remove warnings related to cardiovascular disease, breast cancer, and probable dementia, while retaining the boxed warning for endometrial cancer on systemic estrogen-alone products. On February 12, 2026, the FDA formally approved labeling changes to the first six menopausal HRT products, covering all four categories: systemic combination therapy, systemic estrogen-alone therapy, systemic progestogen-alone therapy, and topical vaginal estrogen therapy. Twenty-nine drug companies submitted proposed labeling changes at the FDA’s request.

Major medical organizations broadly supported the substantive policy change, while some raised process concerns. ⁵ ACOG stated it had “long advocated for removal of the ‘black box warning’ on low-dose vaginal estrogen.” The Menopause Society (formerly NAMS) — which had petitioned the FDA to remove the warnings as far back as 2014 — agreed with the decision, particularly for low-dose vaginal estrogen. The European Menopause and Andropause Society called the decision “a significant scientific and symbolic milestone.” The Society of Gynecologic Oncology acknowledged the shift while emphasizing that “oncologic considerations around risk remain valid” and that treatment decisions must remain individualized.

The FDA bypassed the standard advisory committee process, drawing criticism from medical organizations including ACOG. ⁶ Instead of convening a formal advisory committee meeting governed by the Federal Advisory Committee Act (which requires Federal Register notices, meeting minutes, transcripts, and conflict-of-interest disclosures), the FDA held a two-hour “expert panel” on July 17, 2025. ACOG wrote that “a brief panel such as the two-hour July 17th Expert Panel should not be considered an adequate substitute for an advisory committee meeting.” Dr. Diana Zuckerman of the National Center for Health Research stated that “virtually all [panel] members would benefit financially from the black box warning being eliminated.” Dr. Adriane Fugh-Berman, a Georgetown pharmacology professor, described the panels as “handpicked” to “rubberstamp” preexisting views. FDA Commissioner Makary defended the approach, calling advisory committees “bureaucratic, long, often conflicted and very expensive.”

Strong Inferences

The combination estrogen-plus-progestogen formulations still carry a real, if modest, breast cancer risk that increases with duration of use. ⁷ Long-term WHI follow-up data consistently show that combination HRT increases breast cancer risk, with a hazard ratio of 1.26 in the original trial. The risk rises with prolonged use beyond four to five years and diminishes approximately three years after discontinuation. A 2019 Lancet meta-analysis of worldwide epidemiological evidence confirmed that current and recent past use of all types of menopausal hormone therapy is associated with an increased breast cancer risk, though absolute risk is small for shorter-duration use. The FDA’s removal of the breast cancer warning from combination products is the most contested element of the decision, even among supporters of the broader relabeling.

The administration’s framing of HRT benefits — claiming up to 50% cardiovascular risk reduction, 35% Alzheimer’s reduction, and 50-60% fracture reduction — draws selectively from favorable studies and is contested by some researchers. ⁸ As PolitiFact reported, menopause experts Dr. Nanette Santoro and Dr. Jennifer Howell pushed back against claims of significant cardiovascular and dementia prevention benefits, stating these are “not supported by evidence” to the degree claimed by the FDA announcement. EMAS specifically cautioned that the decision does not mean HRT should be prescribed for cardiovascular disease prevention in asymptomatic women or to prevent cognitive decline, dementia, or frailty. The benefit statistics cited by HHS derive primarily from observational data and age-stratified subgroup analyses rather than from the primary endpoints of randomized controlled trials.

What the Evidence Shows

This is a case where the administration’s substantive policy direction aligns with a genuine, well-documented evolution in medical understanding, but where the process and rhetoric raise legitimate concerns.

The original 2003 black-box warnings were, by current scientific consensus, overly broad. They applied identical warnings to all estrogen-containing products regardless of dose, formulation, or route of administration — grouping low-dose vaginal estrogen (which produces minimal systemic absorption) with high-dose oral systemic formulations. They were based on findings from an older-than-typical study population using formulations that have since been largely superseded. The result was a generation of women — including many younger menopausal women who stood to benefit most — being deterred from or denied access to effective treatment. The medical community had been calling for label revision for over a decade, with the Menopause Society petitioning the FDA as early as 2014.

Where the picture becomes more complicated is in the specifics. The removal of black-box warnings for low-dose vaginal estrogen had near-universal medical support and was uncontroversial. The removal for systemic HRT initiated in younger women close to menopause onset had broad support but with important caveats about individual risk assessment. The removal of the breast cancer warning from combination estrogen-plus-progestogen products was more contentious, given that even updated evidence shows a persistent, duration-dependent increase in breast cancer risk for these formulations. ACOG notably distinguished between vaginal estrogen (strong support for label change) and systemic products (where “risks are not without” and individualized assessment remains essential). EMAS explicitly cautioned that the decision should promote “appropriate prescribing, not maximal prescribing.”

The process concerns are substantive rather than cosmetic. The administration replaced the standard advisory committee process — with its statutory transparency requirements, conflict-of-interest disclosures, and public participation — with a two-hour hand-picked expert panel that critics described as one-sided. ACOG, while supporting the policy outcome, explicitly criticized the process as inadequate. This matters because the strength of evidence-based medicine depends on the integrity of the process by which evidence is evaluated, not just on whether the conclusion happens to be broadly correct.

The Bottom Line

The core action — removing or revising outdated black-box warnings on menopausal HRT that had deterred appropriate use for over two decades — reflects a genuine evolution in medical evidence and had been advocated by major medical organizations since at least 2014. The Menopause Society, ACOG, EMAS, and SGO all expressed varying degrees of support for the substantive change. The evidence that the original warnings were overly broad, based on an older study population, and applied indiscriminately across formulations with very different risk profiles is well-established. To that extent, this is one of the more evidence-aligned actions in the “Making America Healthy Again” portfolio.

The “mostly true but misleading” verdict reflects two significant gaps between the claim and reality. First, the claim presents this as a straightforward empowerment of women’s health, omitting that the process bypassed standard regulatory transparency, that the administration’s benefit claims were selectively overstated, and that combination HRT retains a genuine breast cancer risk the new labeling may understate. Second, the claim implies this was purely a Trump administration achievement, when in fact medical organizations had been pushing for this change for over a decade and the underlying science had shifted well before 2025. The administration acted on an existing scientific consensus — which is a reasonable thing for a government to do — but it did so through a process that substituted hand-picked agreement for rigorous, transparent review.

Footnotes

1. Women’s Health Initiative trial results (2002); FDA black-box warning implementation (2003); WHI hazard ratio data from CancerNetwork reporting. ↩

2. WHI reanalysis data; NCI analysis of estrogen therapy benefits and risks by age; PMC history of HRT. ↩

3. Harvard Health reporting on HRT usage decline; FDA February 2026 press announcement citing 2 million prescriptions vs. 41 million age-eligible women. ↩

4. FDA press announcement, November 10, 2025; FDA labeling changes announcement, February 12, 2026. ↩

5. ACOG statement, November 2025; Menopause Society statement, November 10, 2025; EMAS statement; SGO statement. ↩

6. ACOG process criticism; National Center for Health Research reporting; NPR reporting on Makary defense of expert panels. ↩

7. WHI long-term follow-up breast cancer data; Lancet 2019 meta-analysis; Breastcancer.org expert reactions. ↩

8. PolitiFact analysis, November 19, 2025; EMAS statement caveats on cardiovascular and cognitive claims. ↩